...
首页> 外文期刊>Journal of cellular biochemistry. >Identification of a three‐miRNA signature as a novel potential prognostic biomarker in patients with clear cell renal cell carcinoma
【24h】

Identification of a three‐miRNA signature as a novel potential prognostic biomarker in patients with clear cell renal cell carcinoma

机译:鉴定透明细胞肾细胞癌患者的一种新型潜在预后生物标志物的三miRNA签名

获取原文
获取原文并翻译 | 示例

摘要

Abstract Current studies suggest that some microRNAs (miRNAs) are associated with prognosis in clear cell renal cell carcinoma (ccRCC). In this paper, we aimed to identify a miRNAs signature to improve prognostic prediction for ccRCC patients. Using ccRCC RNA‐Seq data of The Cancer Genome Atlas (TCGA) database, we identified 177 differentially expressed miRNAs between ccRCC and paracancerous tissue. Then all the ccRCC tumor samples were divided into training set and validation set randomly. Three‐miRNA signature including miR130b, miR‐18a, and miR‐223 were constructed by the least absolute shrinkage and selection operator (LASSO) Cox regression model in training set. According to optimal cut‐off value of three‐miRNA signature risk score, all the patients could be classified into high‐risk group and low‐risk group significantly. Survival of patients was significantly different between two groups (hazard ratio, 5.58, 95% confidence interval, 3.17‐9.80; P ??0.0001), and three‐miRNA signature performed favorably prognostic and predictive accuracy. The results were further validated in the validation set and total set. Multivariate Cox regression analyses and subgroup analyses showed that three‐miRNA signature was an independent prognostic factor. Two nomograms that integrated three‐miRNA signature and three clinicopathological risk factors were constructed to predict overall survival and disease‐free survival after surgery for ccRCC patients. Functional enrichment analysis showed the possible roles of three‐miRNA signature in some cancer‐associated biological processes and pathways. In conclusion, we developed a novel three‐miRNA signature that performed reliable prognostic for patient survival with ccRCC, it might facilitate ccRCC patients counseling and individualize management.
机译:摘要目前的研究表明,一些MicroRNAS(miRNA)与透明细胞肾细胞癌(CCRCC)的预后相关。在本文中,我们旨在鉴定MIRNA签名以改善CCRCC患者的预后预测。使用CCRCC RNA-SEQ数据的癌症基因组Atlas(TCGA)数据库,我们在CCRCC和副癌组织之间鉴定了177个差异表达的miRNA。然后将所有CCRCC肿瘤样本分为训练集和验证随机设置。包括MIR130B,MIR-18A和MIR-223的三分之三签名由训练集中的最小绝对收缩和选择操作员(套索)COX回归模型构成。根据三种miRNA签名风险评分的最佳截止值,所有患者均可明显分为高风险组和低风险组。两组(危险比,5.58,95%置信区间,3.17-9.80;p≤≤0.0001),三分之三签名的患者的存活率显着差异显着差异显着差异。结果在验证集和总集中进一步验证。多变量Cox回归分析和亚组分析表明,三分之三签名是一个独立的预后因素。构建了综合三麦麻签名和三种临床病理危险因素的载体图以预测CCRCC患者手术后的整体存活和无病生存。功能性富集分析表明,三麦麻签名在一些癌症相关的生物过程和途径中可能的作用。总之,我们开发了一种新型三分之二的三分之二的签名,对CCRCC进行了患者存活的可靠预后,它可能促进CCRCC患者咨询和个性化管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号